Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo

Caroline Ebert; Florian Perner; Denise Wolleschak; Tina M Schnöder; Thomas Fischer; Florian H Heidel

doi:10.3324/haematol.2015.136754

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo

Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20.

Authors

Caroline Ebert¹, Florian Perner¹, Denise Wolleschak¹, Tina M Schnöder², Thomas Fischer², Florian H Heidel³

Affiliations

¹ Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg.
² Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg Collaborative Research Cluster 854, Medical Faculty, Otto-von-Guericke University Medical Center, Magdeburg.
³ Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg Collaborative Research Cluster 854, Medical Faculty, Otto-von-Guericke University Medical Center, Magdeburg Internal Medicine II, Department of Hematology and Oncology, Friedrich-Schiller-University Jena Current Address: Leibniz-Institute on Aging, Fritz-Lipmann-Institute, Jena, Germany florian.h.heidel@gmail.com.

No abstract available

Keywords: ABCB1; ABCG2; JAK2; T-cell; ruxolitinib.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / genetics
ATP Binding Cassette Transporter, Subfamily B / immunology
ATP Binding Cassette Transporter, Subfamily G, Member 2 / genetics*
ATP Binding Cassette Transporter, Subfamily G, Member 2 / immunology
Antigens, CD / genetics
Antigens, CD / immunology
Antigens, Differentiation, T-Lymphocyte / genetics
Antigens, Differentiation, T-Lymphocyte / immunology
Antineoplastic Agents / pharmacology
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / immunology
CD4-Positive T-Lymphocytes / pathology
CD8-Positive T-Lymphocytes / drug effects
CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / pathology
Cell Proliferation / drug effects
Gene Expression Regulation, Neoplastic*
Humans
Janus Kinase 2 / antagonists & inhibitors
Janus Kinase 2 / genetics
Janus Kinase 2 / immunology
Lectins, C-Type / genetics
Lectins, C-Type / immunology
Lymphocyte Activation / drug effects
Multidrug Resistance-Associated Proteins / genetics*
Multidrug Resistance-Associated Proteins / immunology
Mutation
Neoplasm Proteins / genetics*
Neoplasm Proteins / immunology
Nitriles
Phytohemagglutinins / pharmacology
Polycythemia Vera / drug therapy
Polycythemia Vera / genetics*
Polycythemia Vera / immunology
Polycythemia Vera / pathology
Primary Cell Culture
Primary Myelofibrosis / drug therapy
Primary Myelofibrosis / genetics*
Primary Myelofibrosis / immunology
Primary Myelofibrosis / pathology
Protein Kinase Inhibitors / pharmacology
Pyrazoles / pharmacology*
Pyrimidines
Signal Transduction
Treatment Outcome

Substances

ABCB1 protein, human
ABCG2 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily G, Member 2
Antigens, CD
Antigens, Differentiation, T-Lymphocyte
Antineoplastic Agents
CD69 antigen
Lectins, C-Type
Multidrug Resistance-Associated Proteins
Neoplasm Proteins
Nitriles
Phytohemagglutinins
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
phytohemagglutinin L protein, Phaseolus vulgaris
ruxolitinib
Jak2 protein, mouse
Janus Kinase 2
multidrug resistance-associated protein 1